Sophia Genetics SA (SOPH) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Sophia Genetics SA stock (SOPH) is currently trading at $4.97. Sophia Genetics SA PS ratio (Price-to-Sales) is 4.81. Analyst consensus price target for SOPH is $7.67. WallStSmart rates SOPH as Sell.
- SOPH PE ratio analysis and historical PE chart
- SOPH PS ratio (Price-to-Sales) history and trend
- SOPH intrinsic value — DCF, Graham Number, EPV models
- SOPH stock price prediction 2025 2026 2027 2028 2029 2030
- SOPH fair value vs current price
- SOPH insider transactions and insider buying
- Is SOPH undervalued or overvalued?
- Sophia Genetics SA financial analysis — revenue, earnings, cash flow
- SOPH Piotroski F-Score and Altman Z-Score
- SOPH analyst price target and Smart Rating
Sophia Genetics SA
📊 No data available
Try selecting a different time range
Smart Analysis
Sophia Genetics SA (SOPH) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Sophia Genetics SA (SOPH) Key Strengths (1)
Strong revenue growth at 22.40% annually
Supporting Valuation Data
Sophia Genetics SA (SOPH) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 7.5x book value
Premium valuation at 4.8x annual revenue
Small-cap company with higher risk but more growth potential
Moderate institutional interest at 47.72%
Sophia Genetics SA (SOPH) Detailed Analysis Report
Overall Assessment
This company scores 24/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 8.0/10) while 7 fall into concern territory (avg 2.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 22.40%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (4.81), Price/Book (7.54) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -110.00%, Operating Margin at -85.40%, Profit Margin at -102.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -110.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 22.40% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SOPH Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SOPH's Price-to-Sales ratio of 4.81x sits near its historical average of 4.3x (86th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 4.81x set in Mar 2026, and 26% above its historical low of 3.82x in Mar 2026. Over the past 12 months, the PS ratio has expanded from ~4.2x, reflecting growing market expectations outpacing revenue growth.
Compare SOPH with Competitors
Top HEALTH INFORMATION SERVICES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Sophia Genetics SA (SOPH) · HEALTHCARE › HEALTH INFORMATION SERVICES
The Big Picture
Sophia Genetics SA is a strong growth company balancing expansion with improving profitability. Revenue reached 77M with 22% growth year-over-year. The company is currently unprofitable, posting a -102.2% profit margin.
Key Findings
The company is unprofitable with a -102.2% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -9M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Sophia Genetics SA maintain 22%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor HEALTH INFORMATION SERVICES industry trends, competitive moves, and regulatory changes that could impact Sophia Genetics SA.
Bottom Line
Sophia Genetics SA offers an attractive blend of growth (22% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Sophia Genetics SA(SOPH)
NASDAQ
HEALTHCARE
HEALTH INFORMATION SERVICES
USA
Sophia Genetics SA (SOPH) is a pioneering leader in data-driven medicine, focusing on advanced genomic and clinical data analytics that enhance patient outcomes. Utilizing cutting-edge machine learning algorithms, the company provides a comprehensive platform that aids hospitals and laboratories in interpreting complex genomic data, thus facilitating personalized treatment strategies, especially in oncology, rare diseases, and hereditary disorders. With a strong international footprint and strategic partnerships with premier healthcare organizations, Sophia Genetics is committed to transforming healthcare through precision medicine, solidifying its position as a front-runner in the genomics landscape.